Pfizer

News
FDA approves second Neupogen biosimilar

FDA approves second Neupogen biosimilar

Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.

News
trump_transfer

Trump strikes Pfizer over price increases

The US president took his frustration to twitter criticising Pfizer and “others” for the recent price increase and “taking advantage of Americans”, but there is really not much he can do to